ArticleJournal of virology2026
BKV activates the interferon-β response in primary and immortalized microvascular endothelial cells late in the infectious cycle, resulting in persistence.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Our previous studies have shown that inoculation of primary endothelial cells with BKV results in a long-term persistent infection, with inoculated cultures surviving up to 60 days while producing low levels of infectious viral progeny. Unlike the permissive renal proximal tubule cells, infected endothelial cells activate innate immunity pathways in response to BKV infection. We hypothesized that the innate immune response limits BKV infection, resulting in persistence. In this report, we show that activation of innate immune pathways is not triggered by incoming virus particles but rather occurs at a late stage of the infectious cycle, when viral DNA replication, high levels of late viral transcription, and progeny virion assembly are occurring. Single-cell transcriptomic data indicate that this response varies across the infected cell population, with some cells showing little or no innate immune response, while others appear to be highly activated. Bulk RNA-seq experiments show that the addition of interferon-β to endothelial cells results in the upregulation of a subset of known interferon-stimulated genes (ISGs), as well as many other genes not known to be associated with the interferon response. Finally, we show that the addition of interferon-β blocks BKV infection, so long as it is added prior to or soon after inoculation. These results lead to a model in which BKV infection of endothelial cells results in interferon production and ISG induction that restrict subsequent rounds of infection and lead to a persistent state. IMPORTANCE: BKV infects nearly every human on Earth, and the infection persists throughout life. The cell types where the virus persists remain a mystery, as do the state of the viral genome during persistence, as well as the mechanisms that limit productive infection and maintain persistence. While BKV is known to replicate robustly in renal proximal tubule cells during disease, it is not clear whether the virus persists in these cells. The proximal tubules are located in close proximity to endothelial cells, raising the possibility that BKV persistence occurs in the endothelia, and virus particles from infected endothelia potentially seed infections in the neighboring tubular epithelia during times of cellular stress or immunosuppression. The development of cell culture systems to study the interactions between innate immunity, virus production, and persistence is needed to advance the development of anti-viral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.